Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.77 |
| ▸ | BRD2 | P25440 | 2/20 | 0.53 |
| ▸ | BRD3 | Q15059 | 2/20 | 0.53 |
| ▸ | BRDT | Q58F21 | 2/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.53 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.52 |
| ▸ | BRWD1 | Q9NSI6 | 1/20 | 0.52 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008171 | 0.87 | BRD4 (1.00) | BRD4BRD2BRD3BRDTCREBBP | |
| SCHEMBL15328550 | 0.84 | BRD4 (1.00) | BRD4BRD2BRD3BRDTCREBBP | |
| SCHEMBL16008678 | 0.83 | BRD4 (1.00) | BRD4BRD2BRD3BRDTCREBBP | |
| SCHEMBL15328497 | 0.78 | BRD4 (1.00) | BRD4BRD2BRD3BRDTCREBBP | |
| SCHEMBL15328786 | 0.77 | BRD4 (0.79) | BRD4BRD2BRD3BRDTCREBBP | |
| SCHEMBL15328950 | 0.76 | BRD4 (0.78) | BRD4BRD2BRD3BRDTCREBBP | |
| SCHEMBL15329047 | 0.74 | BRD4 (0.79) | BRD4BRD2BRD3BRDTCREBBP | |
| SCHEMBL16008345 | 0.73 | BRD4 (0.63) | BRD4BRD2BRD3BRDTCREBBP | |
| SCHEMBL16008254 | 0.71 | BRD4 (0.42) | BRD4 | |
| SCHEMBL15328795 | 0.70 | BRD4 (1.00) | BRD4BRD2BRD3BRDTCREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9050346-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-06-09 | — | — | US | claimed |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | claimed |
| US-9050346-B2 | Bromodomain inhibitors | ABBVIE INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | ABBVIE INC. | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256705-A1 | BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | BRD4 1/4885BRD2 5/4885BRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.